Conference on the scientific basis of respiratory therapy. Am Rev Respir Dis1974;110 (suppl):1–202.
2.
WannerA, RaoA.Clinical indications for and effects of bland, mucolytic, and antimicrobial aerosols. Am Rev Respir Dis1980;122:79–87.
3.
LifschitzMI, DenningCR. Safety of kanamycin aerosol. Clin Pharmacol Ther1971;12:91–95.
4.
KilburnKH. The innocuousness and possible therapeutic use of aerosol amphotericin B. Am Rev Respir Dis1959;80:441–442.
5.
GreenfieldS, TeresD, BushnellLS, Hedley-WhyteJ, FeingoldDS. Prevention of gram-negative bacillary pneumonia using aerosol polymyxin as prophylaxis. I. Effect on the colonization pattern of the upper respiratory tract of seriously ill patients. J Clin Invest1973;52:2935–2940.
6.
KlickJM, Du MoulinGC, Hedley-WhyteJ, TeresD, BushnellLS, FeingoldDS. Prevention of gram-negative bacillary pneumonia using polymyxin as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients. J Clin Invest1975;55:514–519.
7.
PinesA, RaafatH, SiddiquiGM, GreenfieldJSB. Treatment of severe Pseudomonas infections of the bronchi. Br Med J1970;1:663–665.
8.
KlasterskyJ, GeuningC, MouawadE, DaneauD.Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest1972;61:117–120.
